Soren Moller1, Ian Law2, Per Munck Af Rosenschold3, Junia Costa4, Hans Skovgaard Poulsen5, Svend Aage Engelholm3, Silke Engelholm6. 1. Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: dr.smoller@gmail.com. 2. Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Denmark. 3. Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark. 4. Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark; Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Denmark. 5. Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark; Department of Radiation Biology, Rigshospitalet, University of Copenhagen, Denmark. 6. Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark; Department of Oncology, Skåne University Hospital, Lund, Sweden.
Abstract
BACKGROUND AND PURPOSE: Positron emission tomography (PET) provides quantitative metabolic information and potential biomarkers of treatment outcome. We aimed to determine the prognostic value of early 18F-fluoroethyl-tyrosine (18F-FET) PET scans acquired during re-irradiation for recurrent high-grade glioma (HGG). MATERIAL AND METHODS: A phase I clinical trial of re-irradiation of HGG was carried out. MRI and 18F-FET PET were used for target delineation and follow-up. Images were acquired at baseline, during radiotherapy and 4weeks post-treatment and compared by measuring the metabolically active biological tumor volume (BTV) and maximal activity (Tmax/B). Correlations with outcomes were assessed by multivariate Cox regression analysis. RESULTS: Thirty-one patients were included and all patients have died. The median overall survival was 7.0 mos. Both baseline BTV and baseline MRI volume (necrotic/cystic cavities subtracted) were prognostic for overall survival (OS) in multivariate analysis (HR=1.3 p<0.01 and HR=1.3 p<0.01, respectively). Early changes in BTV and Tmax/B were observed but they carried no independent prognostic information. CONCLUSIONS: Baseline biological tumor volume (BTV) defined by 18F-FET PET was prognostic for OS in multivariate analysis, as was MRI volume (necrotic/cystic cavities subtracted). Tumor volume may aid in identifying patients whose life expectancy is too short to warrant re-irradiation.
BACKGROUND AND PURPOSE: Positron emission tomography (PET) provides quantitative metabolic information and potential biomarkers of treatment outcome. We aimed to determine the prognostic value of early 18F-fluoroethyl-tyrosine (18F-FET) PET scans acquired during re-irradiation for recurrent high-grade glioma (HGG). MATERIAL AND METHODS: A phase I clinical trial of re-irradiation of HGG was carried out. MRI and 18F-FET PET were used for target delineation and follow-up. Images were acquired at baseline, during radiotherapy and 4weeks post-treatment and compared by measuring the metabolically active biological tumor volume (BTV) and maximal activity (Tmax/B). Correlations with outcomes were assessed by multivariate Cox regression analysis. RESULTS: Thirty-one patients were included and all patients have died. The median overall survival was 7.0 mos. Both baseline BTV and baseline MRI volume (necrotic/cystic cavities subtracted) were prognostic for overall survival (OS) in multivariate analysis (HR=1.3 p<0.01 and HR=1.3 p<0.01, respectively). Early changes in BTV and Tmax/B were observed but they carried no independent prognostic information. CONCLUSIONS: Baseline biological tumor volume (BTV) defined by 18F-FET PET was prognostic for OS in multivariate analysis, as was MRI volume (necrotic/cystic cavities subtracted). Tumor volume may aid in identifying patients whose life expectancy is too short to warrant re-irradiation.
Authors: Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu Journal: Neurosurgery Date: 2019-08-01 Impact factor: 4.654
Authors: Amit Tirosh; Georgios Z Papadakis; Corina Millo; Dima Hammoud; Samira M Sadowski; Peter Herscovitch; Karel Pacak; Stephen J Marx; Lily Yang; Pavel Nockel; Jasmine Shell; Patience Green; Xavier M Keutgen; Dhaval Patel; Naris Nilubol; Electron Kebebew Journal: Gastroenterology Date: 2017-11-16 Impact factor: 22.682
Authors: M Unterrainer; I Winkelmann; B Suchorska; A Giese; V Wenter; F W Kreth; J Herms; P Bartenstein; J C Tonn; N L Albert Journal: Eur J Nucl Med Mol Imaging Date: 2018-02-27 Impact factor: 9.236
Authors: Charlotte Debus; Maria Waltenberger; Ralf Floca; Ali Afshar-Oromieh; Nina Bougatf; Sebastian Adeberg; Sabine Heiland; Martin Bendszus; Wolfgang Wick; Stefan Rieken; Uwe Haberkorn; Jürgen Debus; Maximilian Knoll; Amir Abdollahi Journal: Sci Rep Date: 2018-05-08 Impact factor: 4.379
Authors: Claes N Ladefoged; Flemming L Andersen; Andreas Kjær; Liselotte Højgaard; Ian Law Journal: Front Neurosci Date: 2017-08-11 Impact factor: 4.677
Authors: Daniel F Fleischmann; Marcus Unterrainer; Stefanie Corradini; Maya Rottler; Stefan Förster; Christian la Fougère; Timo Siepmann; Markus Schwaiger; Peter Bartenstein; Claus Belka; Nathalie L Albert; Maximilian Niyazi Journal: PLoS One Date: 2019-07-24 Impact factor: 3.240
Authors: Charlotte Debus; Ali Afshar-Oromieh; Ralf Floca; Michael Ingrisch; Maximilian Knoll; Jürgen Debus; Uwe Haberkorn; Amir Abdollahi Journal: Sci Rep Date: 2018-10-03 Impact factor: 4.379